Open Access

Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis

  • Authors:
    • Xiaowei Xing
    • Shuang Guo
    • Yusheng Liu
    • Jiangying Kuang
    • Zhiwei Huang
    • Xin Wang
    • Qinghua Lu
  • View Affiliations

  • Published online on: July 14, 2021     https://doi.org/10.3892/etm.2021.10422
  • Article Number: 990
  • Copyright: © Xing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Saxagliptin (SAX) can protect against tissue damage caused by diabetic nephropathy. However, whether this compound can restore kidney function, and its specific mechanism of action remain unclear. The present study explored the therapeutic effects and mechanisms of SAX. Male Wistar rats (8 weeks old) were randomly divided into the following groups: A control group (n=10); a group with streptozocin‑induced diabetes mellitus (DM) treated with saline (n=20); and a group with streptozocin‑induced DM treated with SAX (n=20). Following 20 weeks of treatment, renal function and the extent of renal damage were assessed based on histological staining using hematoxylin and eosin, periodic acid‑Schiff and Masson's trichrome staining. The experimental results indicated that Streptozocin induction of DM led to thicker basement membranes in mesangial cells and a more abundant extracellular matrix. These changes were ameliorated following treatment with SAX. The data demonstrated that renal tissue and renal cell apoptosis were ameliorated significantly following treatment with SAX. Furthermore, the expression levels of the apoptotic genes poly (ADP‑ribose) polymerase‑1 (PARP‑1) and caspase 3 were significantly decreased following treatment with SAX. Therefore, SAX may reduce the extent of renal apoptosis and pathological outcomes in diabetic nephropathy by downregulating the expression of caspase 3 and PARP‑1 in the death receptor pathway of apoptosis.

Related Articles

Journal Cover

September-2021
Volume 22 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xing X, Guo S, Liu Y, Kuang J, Huang Z, Wang X and Lu Q: Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis. Exp Ther Med 22: 990, 2021
APA
Xing, X., Guo, S., Liu, Y., Kuang, J., Huang, Z., Wang, X., & Lu, Q. (2021). Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis. Experimental and Therapeutic Medicine, 22, 990. https://doi.org/10.3892/etm.2021.10422
MLA
Xing, X., Guo, S., Liu, Y., Kuang, J., Huang, Z., Wang, X., Lu, Q."Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis". Experimental and Therapeutic Medicine 22.3 (2021): 990.
Chicago
Xing, X., Guo, S., Liu, Y., Kuang, J., Huang, Z., Wang, X., Lu, Q."Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis". Experimental and Therapeutic Medicine 22, no. 3 (2021): 990. https://doi.org/10.3892/etm.2021.10422